The private sector and pharmaceutical industry in Africa
Providing access to quality medicines still poses a number of challenges in Africa. Distribution channels are often fragmented, with a large number of intermediaries or parallel channels, which often fuel counterfeiting – a real public health issue. For example, it is estimated that some 60% of medicines bought in the Gulf of Guinea are classified as “SF” (substandard and falsified) by the World Health Organization (WHO). Furthermore, the problem does not only affect Africa as 10% of all the medicines in circulation around the world could be “SF”.
Lire la revue SP&DMehdi Tanani, Senior Investment Officer and Head of Proparco’s Healthcare division, sets out the major issues tackled in this edition of the magazine.
This new edition of Private Sector & Development tackles all of these issues and attempts to come up with a few pointers and solutions for the future. It lets researchers, associations and public health organisations give their own views and recount their experiences: the whole issue of patents, for example, and private African start-ups such mPharma and Pharmivoire Nouvelle, a pioneering local producer of pharma products in Côte d’Ivoire.published on2018
on the same regionProparco's presentation brochureKey Figurespublished onPress kitspublished onVideospublished onProparco / AFD Group Strategic documentspublished onGovernancePrivate Sector and Developmentpublished onProparco sectoral bookletpublished on
on the same topicVideospublished onPrivate Sector and Developmentpublished onVideospublished onPrivate Sector and Developmentpublished on